Prelude Capital Management’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $518K | Sell |
1,770
-3,148
| -64% | -$1.03M | 0.04% | 490 |
|
|
2025
Q4 | $1.72M | Buy |
+4,918
| New | +$1.66M | 0.13% | 181 |
|
|
2025
Q2 | – | Sell |
-1,470
| Closed | -$639K | – | 1099 |
|
|
2025
Q1 | $639K | Buy |
+1,470
| New | +$590K | 0.05% | 434 |
|
|
2024
Q4 | – | Sell |
-2,245
| Closed | -$1.17M | – | 1295 |
|
|
2024
Q3 | $1.17M | Buy |
+2,245
| New | +$1.2M | 0.07% | 342 |
|
|
2023
Q4 | – | Sell |
-2,870
| Closed | -$1.25M | – | 1176 |
|
|
2023
Q3 | $1.25M | Buy |
2,870
+1,895
| +194% | +$860K | 0.08% | 269 |
|
|
2023
Q2 | $433K | Buy |
975
+282
| +41% | +$130K | 0.03% | 524 |
|
|
2023
Q1 | $319K | Sell |
693
-510
| -42% | -$243K | 0.02% | 623 |
|
|
2022
Q4 | $617K | Buy |
+1,203
| New | +$611K | 0.03% | 487 |
|
|
2022
Q3 | – | Sell |
-3,735
| Closed | -$1.8M | – | 1657 |
|
|
2022
Q2 | $1.8M | Buy |
+3,735
| New | +$1.85M | 0.05% | 333 |
|
|
2022
Q1 | – | Sell |
-898
| Closed | -$416K | – | 1935 |
|
|
2021
Q4 | $416K | Buy |
+898
| New | +$378K | 0.01% | 1123 |
|
|
2021
Q3 | – | Sell |
-3,147
| Closed | -$1.2M | – | 1818 |
|
|
2021
Q2 | $1.2M | Buy |
+3,147
| New | +$1.2M | 0.04% | 518 |
|
|
2021
Q1 | – | Sell |
-892
| Closed | -$286K | – | 1623 |
|
|
2020
Q4 | $286K | Buy |
+892
| New | +$274K | 0.01% | 931 |
|
|
2020
Q3 | – | Sell |
-6,131
| Closed | -$1.61M | – | 1955 |
|
|
2020
Q2 | $1.61M | Buy |
+6,131
| New | +$1.64M | 0.09% | 205 |
|
|
2019
Q3 | – | Sell |
-758
| Closed | -$214K | – | 1792 |
|
|
2019
Q2 | $214K | Buy |
+758
| New | +$207K | 0.01% | 707 |
|
|
2017
Q3 | – | Sell |
-48
| Closed | -$9K | – | 1694 |
|
|
2017
Q2 | $9K | Sell |
48
-466
| -91% | -$83.7K | ﹤0.01% | 1408 |
|
|
2017
Q1 | $85K | Buy |
514
+232
| +82% | +$36.9K | 0.01% | 835 |
|
|
2016
Q4 | $41K | Sell |
282
-4,815
| -94% | -$645K | 0.01% | 1099 |
|
|
2016
Q3 | $639K | Buy |
5,097
+2,004
| +65% | +$259K | 0.07% | 270 |
|
|
2016
Q2 | $406K | Buy |
+3,093
| New | +$423K | 0.06% | 320 |
|
|
2016
Q1 | – | Sell |
-1,010
| Closed | -$141K | – | 1322 |
|
|
2015
Q4 | $141K | Buy |
+1,010
| New | +$139K | 0.02% | 688 |
|
|
2015
Q3 | – | Sell |
-3,161
| Closed | -$519K | – | 1551 |
|
|
2015
Q2 | $519K | Buy |
3,161
+252
| +9% | +$40.3K | 0.07% | 298 |
|
|
2015
Q1 | $449K | Sell |
2,909
-1,989
| -41% | -$283K | 0.06% | 377 |
|
|
2014
Q4 | $616K | Sell |
4,898
-2,185
| -31% | -$270K | 0.09% | 255 |
|
|
2014
Q3 | $847K | Buy |
7,083
+4,808
| +211% | +$551K | 0.12% | 210 |
|
|
2014
Q2 | $245K | Buy |
2,275
+175
| +8% | +$18K | 0.03% | 665 |
|
|
2014
Q1 | $209K | Hold |
2,100
| – | – | 0.03% | 716 |
|
|
2013
Q4 | $194K | Buy |
+2,100
| New | +$187K | 0.03% | 629 |
|
Other funds holding ELV
VCM
VPM
Prelude Capital Management's ELV Position: Q1 2026 in Review
Prelude Capital Management reduced its Elevance Health (ELV) stake by 64% in Q1 2026, selling an estimated $1.03M and leaving 1,770 shares worth $518K. The position accounts for 0.04% of the portfolio, ranked #490.
Prelude Capital Management first reported a position in ELV in Q4 2013 and has held it in 27 quarters since. The position peaked at $1.8M in Q2 2022. 1,464 funds tracked by Wall St. Rank hold ELV as of Q1 2026.
- Prelude Capital Management held 1,770 shares of Elevance Health worth $518K as of Q1 2026.
- Prelude Capital Management sold 3,148 Elevance Health shares in Q1 2026, an estimated $1.03M.
- Elevance Health made up 0.04% of Prelude Capital Management's portfolio in Q1 2026, its #490 holding.
- Prelude Capital Management first reported a position in Elevance Health in Q4 2013 and has held it in 27 quarters since.
- Prelude Capital Management's Elevance Health position peaked at $1.8M in Q2 2022.
- 1,464 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.
Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.